ArticleCancers2016
Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer.
Katelyn D Bothwell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ArticleCancers2016
Katelyn D Bothwell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.